Literature DB >> 31993857

High Neutrophil Count as a Negative Prognostic Factor for Relapse in Patients with Thymic Epithelial Tumor.

Satoru Okada1, Masanori Shimomura1, Hiroaki Tsunezuka1, Shunta Ishihara1, Satoshi Ikebe1, Tatsuo Furuya1, Junichi Shimada1, Satoshi Teramukai2, Masayoshi Inoue3.   

Abstract

PURPOSE: Preoperative neutrophil count is reportedly associated with poor prognosis in cancer patients. This study aimed to investigate the clinical significance of pre-treatment peripheral blood cell counts in patients with thymic epithelial tumors (TETs).
METHODS: A retrospective review of 71 patients with completely resected TETs [64 thymoma, 6 thymic carcinoma, and 1 thymic neuroendocrine tumor] between 2000 and 2018 was conducted. Associations between tumor recurrence and pre-treatment peripheral blood cell counts of leukocytes (WBC), neutrophils (Neut), lymphocytes (Lymph), monocytes (Mono), and platelets (Plt) were analyzed. Optimal cut-off points were selected using receiver operating characteristic curve analysis to predict tumor recurrence.
RESULTS: High WBC (≥ 7000), Neut (≥ 4450), and Plt (≥ 226 × 103) counts had significantly poor relapse-free survival (RFS), but high Lymph (≥ 1950) and Mono (≥ 400) did not. High Neut had the strongest correlation with recurrence (area under curve, 0.800); we focused on the analysis between high-Neut and low-Neut groups. High Neut count significantly correlated with smoking history, pre-treatment C-reactive protein level, and advanced stage; high Neut count and aggressive histology tended to show correlations. RFS was significantly poorer in the high-Neut group than in the low-Neut group (p = 0.003), with 5-year RFS rates of 63.8% and 96.8%, respectively. High Neut count was a significant adverse predictor for RFS and cumulative incidence of recurrence (p = 0.005 and p < 0.001, respectively). The risk scoring system comprising high Neut count, advanced stage, and aggressive histology demonstrated better prognostic ability than any prognostic factors alone.
CONCLUSIONS: High Neut count significantly correlated with TET recurrence, suggesting a negative prognostic effect of latent inflammation in TET patients.

Entities:  

Mesh:

Year:  2020        PMID: 31993857     DOI: 10.1245/s10434-020-08228-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

1.  Prognostic Impact of Using Combined Plasma Fibrinogen Level and Neutrophil-to-Lymphocyte Ratio in Resectable Non-small Cell Lung Cancer.

Authors:  Masashi Iwasaki; Shunta Ishihara; Satoru Okada; Reona Shimegi; Masanori Shimomura; Masayoshi Inoue
Journal:  Ann Surg Oncol       Date:  2022-06-02       Impact factor: 4.339

2.  The nine ADAMs family members serve as potential biomarkers for immune infiltration in pancreatic adenocarcinoma.

Authors:  Bing Qi; Han Liu; Ying Dong; Xueying Shi; Qi Zhou; Fen Zeng; Nabuqi Bao; Qian Li; Yuan Yuan; Lei Yao; Shilin Xia
Journal:  PeerJ       Date:  2020-09-30       Impact factor: 2.984

3.  High preoperative white blood cell count determines poor prognosis and is associated with an immunosuppressive microenvironment in colorectal cancer.

Authors:  Meilin Weng; Wenling Zhao; Ying Yue; Miaomiao Guo; Ke Nan; Qingwu Liao; Minli Sun; Di Zhou; Changhong Miao
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

4.  Pathological tumor long-to-short axis ratio as a prognostic factor in patients with thymic epithelial tumors.

Authors:  Dong Tian; Haruhiko Shiiya; Masaaki Sato; Aya Shinozaki-Ushiku; Hao-Ji Yan; Jun Nakajima
Journal:  Thorac Cancer       Date:  2022-07-21       Impact factor: 3.223

5.  Potential Prognostic Value of Preoperative Leukocyte Count, Lactate Dehydrogenase and C-Reactive Protein in Thymic Epithelial Tumors.

Authors:  Daniel Valdivia; Danjouma Cheufou; Benjamin Fels; Stephan Puhlvers; Khaled Mardanzai; Mohamed Zaatar; Gerhard Weinreich; Christian Taube; Dirk Theegarten; Martin Stuschke; Martin Schuler; Georgios Stamatis; Balazs Hegedus; Clemens Aigner
Journal:  Pathol Oncol Res       Date:  2021-04-21       Impact factor: 3.201

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.